TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06769516

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Low FODMAP Diet Intervention
Description: This intervention involves the implementation of a low FODMAP (fermentable oligo-, di-, mono-saccharides, and polyols) diet to manage symptoms of Irritable Bowel Syndrome (IBS). Participants receive individualized training on the diet before the study begins. The diet eliminates high FODMAP foods known to exacerbate IBS symptoms, such as certain fruits, vegetables, dairy products, and sweeteners, for a duration of 4 weeks.~Participants follow the prescribed dietary protocol under guidance, ensuring adherence and addressing specific nutritional needs. This intervention aims to reduce gastrointestinal distress by limiting fermentable carbohydrates, distinguishing it from other IBS management strategies that do not focus on dietary modifications.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Low FODMAP Diet Intervention
Description: This intervention involves the implementation of a low FODMAP (fermentable oligo-, di-, mono-saccharides, and polyols) diet to manage symptoms of Irritable Bowel Syndrome (IBS). Participants receive individualized training on the diet before the study begins. The diet eliminates high FODMAP foods known to exacerbate IBS symptoms, such as certain fruits, vegetables, dairy products, and sweeteners, for a duration of 4 weeks.~Participants follow the prescribed dietary protocol under guidance, ensuring adherence and addressing specific nutritional needs. This intervention aims to reduce gastrointestinal distress by limiting fermentable carbohydrates, distinguishing it from other IBS management strategies that do not focus on dietary modifications.
Study: NCT06767917

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Eyefill® S.C.
Description: Used as viscoelastic devices during cataract surgery

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Eyefill® M.B.
Description: Used as viscoelastic devices during cataract surgery
Study: NCT06769607

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Investigational algorithm
Description: Investigational algorithm developed for the treatment of Obstructive Sleep Apnea.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Control algorithm
Description: Released algorithm intended for the treament of Obstructive Sleep Apnea
Study: NCT06766097

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: mastic toothpaste
Description: All 30 patients will be randomly assigned to either the mastic toothpaste group A (Mastiha Toothpaste Gingivaction, Mastihashop, Greece) (n = 15) or the placebo Toothpaste group B (from the same manufacturer) (n = 15). All patients will be asked to use the toothpaste triple a day for 14 days and to maintain their usual oral hygiene routine. The measurements will be done in the morning and at least three hours after brushing and without the use of the toothpaste by the participant on the day of the assessments.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo toothpaste
Description: All 30 patients will be randomly assigned to either the mastic toothpaste group A (Mastiha Toothpaste Gingivaction, Mastihashop, Greece) (n = 15) or the placebo Toothpaste group B (from the same manufacturer) (n = 15). All patients will be asked to use the toothpaste triple a day for 14 days and to maintain their usual oral hygiene routine. The measurements will be done in the morning and at least three hours after brushing and without the use of the toothpaste by the participant on the day of the assessments.
Study: NCT05021965

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: different combined of tooth bleaching procedure
Description: The participants will be randomly allocated into 4 groups and receive different kind of tooth bleaching protocol.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: different combined of tooth bleaching procedure
Description: The participants will be randomly allocated into 4 groups and receive different kind of tooth bleaching protocol.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: different combined of tooth bleaching procedure
Description: The participants will be randomly allocated into 4 groups and receive different kind of tooth bleaching protocol.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: different combined of tooth bleaching procedure
Description: The participants will be randomly allocated into 4 groups and receive different kind of tooth bleaching protocol.
Study: NCT06765473

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Misoprostol
Description: preoperative vaginal and postoperative sublingual administration of misoprostol (800 μg) to reducing the amount of blood loss during and 24 hours after CS to determine the optimum time for drug administration.
Study: NCT06765694

Intervention type: DRUG
Intervention: Botulinum toxin injection
Description: first injection was done under ultrasound control in the extensor carpi radialis brevis (ECRB). The second one if necessary was subordinated to clinical examination and focused in one or more of the following: ECRB, extensor digitorum communis, supinator.
Study: NCT06763627

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Gamification ( Board game )
Description: A three- or four-player board game will be designed to teach acute cholecystitis and pancreatitis. The game has two stages: educational (houses 1-9) and reinforcement (houses 10-30). Players roll dice and move their pieces to answer various questions such as multiple-choice, true/false, matching, puzzles, and scenario-based problem-solving. Each player starts with three hearts, and if they land on one of the three red trap spaces and answer incorrectly, they lose one heart. Yellow spaces introduce random events like gaining or losing hearts. One space features a general knowledge question for variety. Players must achieve a point threshold in the educational section to move to the reinforcement section, and the highest scorer at the end of the hour wins. Groups of 3 or 4 students will play for one hour under the supervision of the investigator.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Traditional lecture-based teaching
Description: Students will attend a standard one-hour lecture delivered by a general surgery faculty member, covering the same topics. PowerPoint presentations prepared by the research team will ensure consistency with the game content.
Study: NCT06765031

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Furosemide
Description: Furosemide will be administered intravenously in the form of a push at a dose of 1 mg/kg to furosemide-naïve patients who meet the inclusion criteria and at a dose of 1.5 mg/kg to patients exposed to furosemide.
Study: NCT06766448

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: robotic training
Description: a rehabilitation program combining continuous passive mobilization, robotic therapy and self-program booklet

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: conventionnal rehabilitation
Description: rehabilitation sessions include pain-relieving physiotherapy, passive mobilization, active functional work, and self-programmed learning with a physiotherapist
Study: NCT06768320

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lomaira 8Mg Tablet
Description: 8 mg tablet up to three times a day
Study: NCT06765135

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Clinician Survey
Description: At the conclusion of the intervention period, practice stakeholders, including survey providers and practice managers in the intervention sites will be surveyed to identify their degree of satisfaction with the intervention and suggestions for improvement.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Focus Group
Description: Prior to installing the device in each primary care practice, trained moderators will conduct focus groups with clinicians and practice staff to to elicit provider perceptions of POC testing for respiratory pathogens, including feasibility and acceptability of integration of testing into routine workflows.

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Biofire Spotfire Respiratory (R) panel
Description: Eligible patients will be offered testing with the BioFire Spotfire Respiratory (R) Panel, which is an FDA-cleared, CLIA waived test. This is a multiplexed polymerase chain reaction (PCR) test intended for use with the BioFire Spotfire System for the simultaneous, qualitative detection and identification of multiple respiratory viral and bacterial nucleic acids in nasopharyngeal (NP) swab specimens obtained from individuals with signs and symptoms of respiratory tract infection, including COVID-19. This testing will be made available in participating practices along with clinical guidance about use and interpretation. Clinicians will administer the tests to patients who agree to be tested. Results will be shared with patients, who can discuss the results with their clinicians. Clinicians can use the test results to guide their treatment decisions.

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Biofire Spotfire Respiratory (R) panel
Description: Eligible patients will be offered testing with the BioFire Spotfire Respiratory (R) Panel, which is an FDA-cleared, CLIA waived test. This is a multiplexed polymerase chain reaction (PCR) test intended for use with the BioFire Spotfire System for the simultaneous, qualitative detection and identification of multiple respiratory viral and bacterial nucleic acids in nasopharyngeal (NP) swab specimens obtained from individuals with signs and symptoms of respiratory tract infection, including COVID-19. This testing will be made available in participating practices along with clinical guidance about use and interpretation. Clinicians will administer the tests to patients who agree to be tested. Results will be shared with patients, who can discuss the results with their clinicians. Clinicians can use the test results to guide their treatment decisions.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Patient Survey
Description: During the intervention period, patients who undergo POC RPP testing will be surveyed soon after their visit to elicit their opinions about the test.
Study: NCT06767995

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Flexible fiberoptic bronchoscopy
Description: If Flexible Intubation Video Endoscope® (FIVE) will be used, the appropriate endotracheal tube is loaded into the bronchoscope and made ready. The number of attempts and duration of successful intubation were recorded by a non-blinded research assistant. The stopwatch was started when the FFB started to pass through the patient's mouth/nose, and as soon as the ventilation of the lungs was confirmed by the end tidal carbon dioxide trace, the stopwatch was stopped and this time was recorded as the successful intubation time. The time between passing FFB through the mouth/nose and obtaining the best glottic view was recorded as the best glottic visualization time. The endotracheal tube passage time was defined as the intubation time minus the best glottic visualization time and recorded. Complications during the procedure were recorded.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Glidescope
Description: If GlideScope® Titanium is to be used, a 50-60° angle is applied with the appropriate stylet, and the appropriate one from 3 pediatric blade sizes is selected according to the clinical experience of the relevant practitioner. The number of attempts and duration of successful intubation were recorded by a non-blinded research assistant. The stopwatch was started as soon as the videolaryngoscope started to pass through the patient's mouth, and the stopwatch was stopped as soon as the ventilation of the lungs was confirmed by the end tidal carbon dioxide trace, and this time was recorded as the successful intubation time. The time between passing the videolaryngoscope through the mouth/nose and obtaining the best glottic view was recorded as the best glottic visualization time. Endotracheal tube transit time was defined as intubation time minus best glottic visualization time and recorded. Complications during the procedure were recorded.
Study: NCT06765564

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: iPSC-MNP
Description: Using iPSC-MNP Cells for the Treatment of ALS Patients
Study: NCT06769802

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Experimental
Description: The children in this group and their mothers will be informed about the research and their written consent will be obtained. The scale will be filled in before the application. Before the application, Nebul will introduce the teddy bear to the mother and child. The teddy bear cannot be washed because it contains an electronic device. Therefore, it will be disinfected with a solution containing 60-70% alcohol before and after use. The recorded voice will then be played to the child and mother. Then, routine nebulizer treatment will be applied and the second audio recording will be played at the end of the treatment. The researcher will be with the child.~At the end of the nebulizer treatment, after the mask is removed, the Child Fear Scale and the Child Anxiety Scale-State Scale will be filled out. The Child Fear Scale will be filled in by both the mother and the nurse and the average will be taken.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: The children in this group and their parents will be informed about the research and their written consent will be obtained. Scales will be filled in before application. Children in this group will receive routine nebulizer treatment and routine application will be performed. At the end of the treatment, the scales will be filled in again.
Study: NCT06767761

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GZR4
Description: GZR4 s.c., once-weekly，treat-to-target dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin Glargine U100 group
Description: Insulin Glargine U100 s.c.,once-daily，treat-to-target dose
Study: NCT06768983

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Description: 10 sessions of remotely delivered CBT; each session is about 45 minutes in length. The aim of the sessions is to cultivate skills that promote activity and reduce fatigue and its impact on daily activities.
Study: NCT06769425

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HS-10502 + NHA
Description: HS-10502 + NHA

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HS-10502 + HS-20093
Description: HS-10502 + HS-20093

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HS-10502+ Apatinib
Description: HS-10502+ Apatinib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HS-10502 + HS-20089
Description: HS-10502 + HS-20089

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HS-10502 + Platinum + Bevacizumab
Description: HS-10502 + Platinum + Bevacizumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HS-10502 + nab-paclitaxel or Docetaxel or Irinotecan
Description: HS-10502 + nab-paclitaxel or Docetaxel or Irinotecan
Study: NCT06769503

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: aromatherapy
Description: Lavender oil dropped on gauze will be smelled for approximately 3-5 minutes.
Study: NCT06768307

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: First-line Immunotherapy Combined with Chemoradiotherapy for ES-SCLC
Description: Cohort 1:~Induction Phase: Patients will receive three cycles of atezolizumab in combination with carboplatin/cisplatin plus etoposide.~Concurrent Radiotherapy Phase: the fourth cycle will incorporate concurrent radiotherapy along with atezolizumab and chemotherapy.~Maintenance Phase: Atezolizumab monotherapy will be administered until disease progression or intolerance by the patient, with atezolizumab being administered for a maximum duration of 2 years.~Cohort 2:~Induction Phase: Patients will receive three cycles of atezolizumab in combination with carboplatin/cisplatin plus etoposide.~Sequential Radiotherapy Phase: the fourth cycle will receive sequential radiotherapy in combination with atezolizumab.Final，Atezolizumab monotherapy will be continued until disease progression.
Study: NCT06768567

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: effect of hemostasis time on outcome of partial pulpotomy in teeth with clinical signs indicative of irreversible pulpitis.
Description: After caries removal and pulp exposure pulp tissue is amputated and pulpal wound will be irrigated with 3% NaOCl, and bleeding will be controlled by placing a cotton pellet soaked with 3% NaOCl over the pulpal wound for 2 to 3 minutes and will be repeated if required and time taken to achieve hemostasis will be recorded using stop watch. Teeth in which bleeding will be controlled witin 6 mins will be placed in Group A, while those in which it gets controlled between 6 to 12 mins will be included in Group B. Root canal therapy will be initiated in cases in which haemostasis is not achieved even after 12 minutes. Followed by capping with 2-3mm layer of MTA. A layer of RMGIC will be placed over the MTA. Then the tooth will be permanently restored with composite resin.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: effect of hemostasis time on outcome of partial pulpotomy in teeth with clinical signs indicative of irreversible pulpitis.
Description: After caries removal and pulp exposure pulp tissue is amputated and pulpal wound will be irrigated with 3% NaOCl, and bleeding will be controlled by placing a cotton pellet soaked with 3% NaOCl over the pulpal wound for 2 to 3 minutes and will be repeated if required and time taken to achieve hemostasis will be recorded using stop watch. Teeth in which bleeding will be controlled witin 6 mins will be placed in Group A, while those in which it gets controlled between 6 to 12 mins will be included in Group B. Root canal therapy will be initiated in cases in which haemostasis is not achieved even after 12 minutes. Followed by capping with 2-3mm layer of MTA. A layer of RMGIC will be placed over the MTA. Then the tooth will be permanently restored with composite resin.
Study: NCT06767501

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: E-GRAFT ™
Description: E-GRAFT™ that is a dehydrated thick amniotic allograft processed and approved for use as a Human Cellular and Tissue-Based Product (HCT/P) under FDA 21 CFR 1271 and Section 361 of the Public Health Service (PHS) Act.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: FIBRACOL™
Description: 510K FDA cleared Collagen alginate dressing
Study: NCT06766201

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Metformin mixed with propylene glycol
Study: NCT06765525

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Junior sonographer measurement of DDH
Description: Participants will not receive visual cues from the DeepDDH system. Junior sonographer technicians will offer preliminary interpretations before these are subjected to validation and subsequent review by expert's team.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Senior sonographer measurement of DDH
Description: Participants will not receive visual cues from the DeepDDH system.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Automated annotation of the DDH measurement through deep learning
Description: Through randomization, a subset of the preliminary interpretations will be conducted by AI technology, and the study team will evaluate the degree of divergence between these AI-generated preliminary interpretations and the final interpretations.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: AI-assisted junior sonographer meaturement of DDH
Description: Participants will receive visual cues from the DeepDDH system.
Study: NCT06765941

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Probe-based near-infrared parathyroid autofluorescence detection system
Description: The surgeon will use the PTeye as an intraoperative tool to identify whether a suspect tissue is parathyroid or not during the surgery. The surgeon will first take five baseline NIRAF measurements on the thyroid gland (or neck muscle, if thyroid is absent), to establish a reference point for subsequent measurements, using the disposable sterile fiber probe that is connected to the PTeye console, as per device functionality requirements. The subsequent step involves touching the target tissue in the neck with the fiber optic probe, after which the PTeye will indicate to the surgeon whether the tissue is parathyroid or not. Parameters displayed on the PTeye console - Baseline values, Detection Intensity, Parathyroid Detection Ratio - will be recorded for each patient in the study arm. PTeye indicates that a tissue is parathyroid if the 'Parathyroid Detection Ratio' is greater than 1.2. The rest of the surgical procedure will follow the standard protocol.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgeons naked eyes for parathyroid glands identification
Description: The surgeons will not use the probe-based near-infrared parathyroid autofluorescence detection system and will proceed with the procedure as usual, relying on their surgical experience to identify parathyroid glands. At the end of the procedure, the thyroid specimen will be evaluated visually to search for inadvertently resected parathyroid glands. If this is the case, these parathyroid glands will be reimplanted in the sternocleidomastoid muscle, following standard protocol.
Study: NCT06763783

Intervention type: DRUG
Group type: OTHER
Intervention: Shingrix
Description: all participants vaccinates with two doses of Shingrix vaccine

Intervention type: DRUG
Group type: OTHER
Intervention: vaccination with 2 doses of Shingrix vaccine
Description: all participants will receive vaccination with 2 doses of Shingrix vaccine. The response to caccine will be compared bitween patients treated with immunosupressive drugs and these not receiving immunosuppresive treatment
Study: NCT06769152

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HLX43 DOSE 1
Description: HLX43 is an anti-PD-L1 monoclonal antibody conjugated with a novel high potency DNA topoisomerase I (topo I) inhibitor, with a drug-antibody-ratio (DAR) of 8.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HLX43 DOSE 2
Description: HLX43 is an anti-PD-L1 monoclonal antibody conjugated with a novel high potency DNA topoisomerase I (topo I) inhibitor, with a drug-antibody-ratio (DAR) of 8.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HLX43 DOSE 3
Description: HLX43 is an anti-PD-L1 monoclonal antibody conjugated with a novel high potency DNA topoisomerase I (topo I) inhibitor, with a drug-antibody-ratio (DAR) of 8.
Study: NCT06767696

Intervention type: OTHER
Intervention: Cuff pressure measurement
Description: Intubation tube cuff pressure in cmH2O at 3 different time periods with a cuff manometer (VBM Medizintechnik, GmbH, Germany)~Time periods:~Cuff pressure value measured in neutral position after intubation (cmH2O) - T0 Cuff pressure measurement value after hyperextension (cmH2O) - T1 Cuff pressure measurement value in neutral position after surgical procedure (cmH2O) - T2